The Results of Stricter Inclusion Criteria in an Immunomagnetic Detection Study of Micrometastatic Cells in Bone Marrow of Uveal Melanoma Patients - Relevance for Dormancy

Autor: Leiv Sandvik, Peter Jebsen, Nils Eide, Øystein Fodstad, Rowan Thomas Faber, Geir A. Qvale, Hanne K. Høifødt, Gunnar Kvalheim, Ragnar S. Faye
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
Adult
Male
Uveal Neoplasms
Cancer Research
medicine.medical_specialty
Pathology
Adolescent
Bone Marrow Cells
Immunomagnetic separation
Peripheral blood mononuclear cell
Pathology and Forensic Medicine
03 medical and health sciences
Young Adult
0302 clinical medicine
Internal medicine
medicine
Biomarkers
Tumor
Humans
Prospective Studies
Melanoma
Aged
Aged
80 and over
business.industry
Immunomagnetic Separation
Micrometastasis
Cancer
Neoplasms
Second Primary
General Medicine
Middle Aged
medicine.disease
Neoplastic Cells
Circulating
Prognosis
Log-rank test
Survival Rate
030104 developmental biology
medicine.anatomical_structure
Neoplasm Micrometastasis
030220 oncology & carcinogenesis
Cohort
Female
Bone marrow
Neoplasm Recurrence
Local
business
Bone Marrow Neoplasms
Follow-Up Studies
Zdroj: Pathology oncology research : POR. 25(1)
ISSN: 1532-2807
Popis: Approximately 50% of uveal melanoma patients develop metastases. We want to evaluate the effect of stricter criteria on our data from our previous study correlating survival and bone marrow (BM) micrometastasis results using our immunomagnetic separation (IMS) method. Mononuclear cell fractions (MNC) isolated from BM were examined for tumour cells and the patients were classified as BM positive (BM+) or BM negative (BM-). The study originally included 328 consecutive patients with uveal melanoma from 1997 to 2006. The cohort was limited to 217 patients when we introduced cyto- or histopathological verification of melanoma cells in the patient as a main new criterion for inclusion. Tumour cells were found in BM-samples in 38.7% (95% CI, 32–45) at enrolment. Until the latest work-up 43.8% (95% CI, 38–50) of patients had developed melanoma metastases. After a minimum follow-up time of 8.5 years, 60.4% (95% CI, 54–66) of patients had died. The causes were: melanoma metastases 69.5%, another type of cancer 5.4% and non-cancerous causes 19.5%. Overall median survival was shorter for the BM- patients (11.3 years) (95% CI, 10–12) compared to the BM+ (16.5 years) (95% CI, 12–14), p = 0.04, log rank test. All-cause mortality and specific melanoma mortality estimated after 12 year follow-up showed a highly significant difference comparing BM- and BM+, p = 0.010 and p = 0,017, respectively. IMS yields a high fraction of BM+ samples due to micrometastasis at diagnosis and these cells appear to have a positive prognostic impact strengthening our previous report. The late recurrences support the concept of tumour dormancy.
Databáze: OpenAIRE
Externí odkaz: